Qingdao, China

Weiyun Shi

This inventor holds 3 USPTO granted patents and 7 published patent applications and 1 EPO patent. Top assignees: Eye Institute of Shandong First Medical University, Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute of Ophthalmo, Institute of Ophthalmology Affiliated to Shandong First Medical University (Shandong Institute of Ophthalmology, Qingdao Eye Hospital Affiliated to Shandong First Medical University). Active years: 2023-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Weiyun Shi. Retrieved from https://idiyas.com/inventor/weiyun-shi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.5

ph-index = 1


Location History:

  • Shandong, CN (2023)
  • Qingdao, CN (2024)

Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Weiyun Shi: Innovator in Ophthalmology

Introduction

Weiyun Shi is a prominent inventor based in Qingdao, China, known for his significant contributions to the field of ophthalmology. With a total of three patents to his name, he has focused on developing innovative solutions for corneal neovascularization and related eye conditions. His work aims to improve treatment methods and enhance patient outcomes.

Latest Patents

One of Weiyun Shi's latest patents is the "Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)." This invention addresses the complications associated with current treatment methods for CNV. The CB-839-loaded drug has shown promising results in significantly inhibiting CNV in mice while reducing inflammatory cell infiltration without notable side effects. This advancement overcomes limitations found in prior art.

Another notable patent is the "Preparation method of nanozyme composite-based hybrid hydrogel eye drop." This method involves synthesizing a tannin-coordinated silver/cobalt composite nanoparticle through a series of chemical reactions. The resulting eye drop demonstrates a broad-spectrum bactericidal effect against various bacteria and fungi, proving effective in preventing and treating bacterial and drug-resistant bacterial corneal infections.

Career Highlights

Weiyun Shi has worked at the Institute of Ophthalmology Affiliated to Shandong First Medical University, specifically at the Shandong Institute of Ophthalmology and Qingdao Eye Hospital. His experience in these esteemed institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in ophthalmology.

Collaborations

Throughout his career, Weiyun Shi has collaborated with notable colleagues, including Qingjun Zhou and Hongwei Wang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pursuit of advancing ophthalmic treatments.

Conclusion

Weiyun Shi's contributions to ophthalmology through his innovative patents and collaborative efforts highlight his commitment to improving eye care. His work not only addresses existing challenges but also paves the way for future advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…